CF Patients' COVID antibodies tracked in Two-Year study
NCT ID NCT05054582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether people with cystic fibrosis (CF) have COVID-19 antibodies from infection or vaccination. Researchers followed 152 adults and children with CF for two years, taking blood samples every six months. They aimed to understand how many had antibodies, how long they lasted, and how COVID-19 affected their CF symptoms. The study did not test any new treatment but gathered important information to guide care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CF Centre Innsbruck, Medical University of Innsbruck, Univ. Clinic for Paediatics III
Innsbruck, Tyrol, 6020, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?
- E-Ink screens in ERs could boost patient satisfaction